• Nasdaq granted Rani Therapeutics an additional 180 days, until May 10, 2027, to regain compliance with its minimum bid price requirement.
• The Class A common stock listing transferred from Nasdaq Global Market to Nasdaq Capital Market effective November 12, 2026.
• Compliance requires a closing bid price of at least $1 per share for at least 10 consecutive business days.
• Nasdaq may require a longer compliance period, generally no more than 20 consecutive business days.
• The company has committed to curing the deficiency, including through a reverse stock split if necessary.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-458489), on November 12, 2026, and is solely responsible for the information contained therein.